Comparative Pharmacology
Head-to-head clinical analysis: ADVAIR DISKUS 500 50 versus NEOMYCIN SULFATE TRIAMCINOLONE ACETONIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVAIR DISKUS 500 50 versus NEOMYCIN SULFATE TRIAMCINOLONE ACETONIDE.
ADVAIR DISKUS 500/50 vs NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Salmeterol is a long-acting beta2-adrenergic receptor agonist that stimulates intracellular adenyl cyclase, increasing cyclic AMP, leading to bronchodilation. Fluticasone propionate is a corticosteroid with anti-inflammatory activity, inhibiting inflammatory cell infiltration and mediator release.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Triamcinolone acetonide is a corticosteroid that induces phospholipase A2 inhibitory proteins, thereby decreasing prostaglandin and leukotriene synthesis, and exerts anti-inflammatory, antipruritic, and vasoconstrictive effects.
ADVAIR DISKUS 500/50: One inhalation (fluticasone propionate 500 mcg and salmeterol 50 mcg) twice daily (approximately 12 hours apart).
Topical: Apply thin film to affected area 2-4 times daily. Otic: Instill 3-4 drops into ear canal 2-3 times daily. Not for systemic use.
None Documented
None Documented
Fluticasone propionate: terminal elimination half-life is approximately 7.8 hours. Salmeterol: terminal elimination half-life is approximately 5.5 hours. Clinically, the half-life supports twice-daily dosing for sustained bronchodilation and anti-inflammatory effects.
Neomycin: 2-3 hours (normal renal function); in renal impairment, prolonged up to 12-24 hours. Triamcinolone acetonide: 2-5 hours (terminal).
Fluticasone propionate: primarily hepatic (cytochrome P450 3A4) metabolism; renal excretion accounts for <5% as unchanged drug; fecal excretion accounts for the majority as metabolites. Salmeterol: primarily hepatic metabolism; renal excretion accounts for approximately 25% of the dose; fecal excretion accounts for approximately 60%.
Neomycin: >90% orally administered excreted unchanged in feces; absorbed fraction (3-6%) excreted renally with 50% within 24 hours. Triamcinolone acetonide: primarily hepatic metabolism, renal excretion of metabolites (~40% as 11-keto derivatives), fecal excretion ~20%.
Category C
Category D/X
Corticosteroid/LABA Combination
Corticosteroid